Arteaga CL - Search Results

1

HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. Hyman DM, et al. Among authors: arteaga cl. Nature. 2018 Feb 8;554(7691):189-194. doi: 10.1038/nature25475. Epub 2018 Jan 31. Nature. 2018. PMID: 29420467 Free PMC article. Clinical Trial.

2

Growth retardation and tumour inhibition by BRCA1.

Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King MC, Jensen RA. Holt JT, et al. Among authors: arteaga cl. Nat Genet. 1996 Mar;12(3):298-302. doi: 10.1038/ng0396-298. Nat Genet. 1996. PMID: 8589721

3

Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.

Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Yakes FM, et al. Among authors: arteaga cl. Cancer Res. 2002 Jul 15;62(14):4132-41. Cancer Res. 2002. PMID: 12124352

4

PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.

Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL. Shin I, et al. Among authors: arteaga cl. Nat Med. 2002 Oct;8(10):1145-52. doi: 10.1038/nm759. Epub 2002 Sep 16. Nat Med. 2002. PMID: 12244301

5

Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice.

Arteaga CL, Baselga J. Arteaga CL, et al. Clin Cancer Res. 2003 May;9(5):1579-89. Clin Cancer Res. 2003. PMID: 12738709 Review. No abstract available.

6

Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?

Arteaga CL, Baselga J. Arteaga CL, et al. Cancer Cell. 2004 Jun;5(6):525-31. doi: 10.1016/j.ccr.2004.05.028. Cancer Cell. 2004. PMID: 15193255 Free article.

7

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.

Baselga J, Arteaga CL. Baselga J, et al. Among authors: arteaga cl. J Clin Oncol. 2005 Apr 10;23(11):2445-59. doi: 10.1200/JCO.2005.11.890. Epub 2005 Mar 7. J Clin Oncol. 2005. PMID: 15753456 Review.

8

Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity.

Wu FY, Wang SE, Sanders ME, Shin I, Rojo F, Baselga J, Arteaga CL. Wu FY, et al. Among authors: arteaga cl. Cancer Res. 2006 Feb 15;66(4):2162-72. doi: 10.1158/0008-5472.CAN-05-3304. Cancer Res. 2006. PMID: 16489017

9

Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors.

Yang S, Qu S, Perez-Tores M, Sawai A, Rosen N, Solit DB, Arteaga CL. Yang S, et al. Among authors: arteaga cl. Cancer Res. 2006 Jul 15;66(14):6990-7. doi: 10.1158/0008-5472.CAN-06-1042. Cancer Res. 2006. PMID: 16849543

10

relocating job wise? A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor.

Hinow P, Wang SE, Arteaga CL, Webb GF. Hinow P, et al. Among authors: arteaga cl. Theor Biol Med Model. 2007 Apr 3;4:14. doi: 10.1186/1742-4682-4-14. Theor Biol Med Model. 2007. PMID: 17407594 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

414 results

Search Page